Pfizer's (PFE.US) $43 billion Seagen (SGEN.US) deal wins unconditional EU approval. As it was concluded by European lawmakers, deal wouldn't raise competition concerns or higher prices for oncology drugs.
Source: xStation5
Novo Nordisk - There Were Risks, Now It's Time for Opportunities.
US OPEN: Renewed optimism at the beginning of the week
Nvidia: Potential H200 Shipments to China in the Spotlight
Daily Summary: Wall Street Rises on Christmas Mood